These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 9687395)
1. Sensitivity of Leishmania viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexes. Lucumi A; Robledo S; Gama V; Saravia NG Antimicrob Agents Chemother; 1998 Aug; 42(8):1990-5. PubMed ID: 9687395 [TBL] [Abstract][Full Text] [Related]
2. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Ephros M; Bitnun A; Shaked P; Waldman E; Zilberstein D Antimicrob Agents Chemother; 1999 Feb; 43(2):278-82. PubMed ID: 9925518 [TBL] [Abstract][Full Text] [Related]
3. Effect of glucantime on field and patient isolates of New World Leishmania: use of growth parameters of promastigotes to assess antimony susceptibility. Moreira ES; Anacleto C; Petrillo-Peixoto ML Parasitol Res; 1998 Sep; 84(9):720-6. PubMed ID: 9766900 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents. Walker J; Saravia NG J Parasitol; 2004 Oct; 90(5):1155-62. PubMed ID: 15562618 [TBL] [Abstract][Full Text] [Related]
5. [Differential expression of proteins in Leishmania (Viannia) panamensis associated with mechanisms of resistance to meglumine antimoniate]. Peláez RG; Muskus CE; Cuervo P; Marín-Villa M Biomedica; 2012 Sep; 32(3):418-29. PubMed ID: 23715190 [TBL] [Abstract][Full Text] [Related]
6. Sensitivity to Glucantime of Leishmania viannia isolated from patients prior to treatment. Robledo SM; Valencia AZ; Saravia NG J Parasitol; 1999 Apr; 85(2):360-6. PubMed ID: 10219320 [TBL] [Abstract][Full Text] [Related]
7. Glucantime resistant Leishmania promastigotes are sensitive to pentostam. Moreira ES; Guerra JB; Petrillo-Peixoto Mde L Rev Soc Bras Med Trop; 1992; 25(4):247-50. PubMed ID: 1340539 [TBL] [Abstract][Full Text] [Related]
8. Leishmania (V.) guyanensis: isolation and characterization of glucantime-resistant cell lines. Ferreira-Pinto KC; Miranda-Vilela AL; Anacleto C; Fernandes AP; Abdo MC; Petrillo-Peixoto ML; Moreira ES Can J Microbiol; 1996 Sep; 42(9):944-9. PubMed ID: 8864217 [TBL] [Abstract][Full Text] [Related]
9. Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis. Fernández OL; Rosales-Chilama M; Sánchez-Hidalgo A; Gómez P; Rebellón-Sánchez DE; Regli IB; Díaz-Varela M; Tacchini-Cottier F; Saravia NG PLoS Negl Trop Dis; 2024 May; 18(5):e0012156. PubMed ID: 38709850 [TBL] [Abstract][Full Text] [Related]
10. Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia. Fernández OL; Diaz-Toro Y; Ovalle C; Valderrama L; Muvdi S; Rodríguez I; Gomez MA; Saravia NG PLoS Negl Trop Dis; 2014 May; 8(5):e2871. PubMed ID: 24853871 [TBL] [Abstract][Full Text] [Related]
11. Cell surface carbohydrates and in vivo infectivity of glucantime-sensitive and resistant Leishmania (Viannia) guyjanensis cell lines. Gazola KC; Ferreira AV; Anacleto C; Michalick MS; Andrade AF; Moreira ES Parasitol Res; 2001 Nov; 87(11):935-40. PubMed ID: 11728019 [TBL] [Abstract][Full Text] [Related]
12. Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility. Barrera MC; Rojas LJ; Weiss A; Fernandez O; McMahon-Pratt D; Saravia NG; Gomez MA Acta Trop; 2017 Dec; 176():355-363. PubMed ID: 28843396 [TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate. Carrió J; Portús M BMC Pharmacol; 2002 May; 2():11. PubMed ID: 12019027 [TBL] [Abstract][Full Text] [Related]
14. Leishmania (Viannia) panamensis: an in vitro assay using the expression of GFP for screening of antileishmanial drug. Varela M RE; Muñoz DL; Robledo SM; Kolli BK; Dutta S; Chang KP; Muskus C Exp Parasitol; 2009 Jun; 122(2):134-9. PubMed ID: 19303871 [TBL] [Abstract][Full Text] [Related]
15. Glucantime susceptibility of Leishmania promastigotes under variable growth conditions. Moreira ES; Soares RM; Petrillo-Peixoto Mde L Parasitol Res; 1995; 81(4):291-5. PubMed ID: 7624285 [TBL] [Abstract][Full Text] [Related]
16. An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1. Gebre-Hiwot A; Tadesse G; Croft SL; Frommel D Acta Trop; 1992 Aug; 51(3-4):237-45. PubMed ID: 1359751 [TBL] [Abstract][Full Text] [Related]
17. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of meglumine antimoniate, a pentavalent antimonial drug, on Leishmania promastigotes. Moreira ES; Petrillo-Peixoto ML Braz J Med Biol Res; 1991; 24(5):459-69. PubMed ID: 1823261 [TBL] [Abstract][Full Text] [Related]
19. Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp. Fernández O; Diaz-Toro Y; Valderrama L; Ovalle C; Valderrama M; Castillo H; Perez M; Saravia NG J Clin Microbiol; 2012 Jul; 50(7):2207-11. PubMed ID: 22518860 [TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of the effectiveness and cytotoxicity of meglumine antimoniate microspheres produced by spray drying against Leishmania infantum. Pujals G; Suñé-Negre JM; Pérez P; García E; Portus M; Tico JR; Miñarro M; Carrió J Parasitol Res; 2008 May; 102(6):1243-7. PubMed ID: 18278586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]